{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"LB Pharmaceuticals Inc"},"Symbol":{"label":"Symbol","value":"LBRX"},"Address":{"label":"Address","value":"ONE PENNSYLVANIA PLAZA,SUITE #1025, NY, New York, 10119, United States"},"Phone":{"label":"Phone","value":"(212) 605-0300"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases."},"CompanyUrl":{"label":"Company Url","value":"https://lbpharma.us/"}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}